endoscopy procedure News
-
EvoEndo Raises $10.1 Million to Make Unsedated Transnasal Endoscopy a Reality for Patients and Physicians
EvoEndo Inc., (“EvoEndo” or “the Company”) a preclinical medical device company developing systems for unsedated Transnasal Endoscopy (TNE), announced it has secured $10.1M in equity financing. The funding round, which included a variety of family offices and early-stage life science investors, will be used to further EvoEndo’s innovative technology designed to help ...
By EvoEndo
-
EvoEndo Poised to Transform Clinical Endoscopy Practice with the EvoEndo Single-Use Unsedated Transnasal Endoscopy (TNE) System
EvoEndo, Inc. (“EvoEndo”), a medical device company which developed a single use system that allows for unsedated Transnasal Endoscopy (TNE), has announced the completion of an $8.4 million Series A financing round led by founding investor TLP Investment Partners LLC (TLP) and including the Sunshine Charitable Foundation and the Jill and Paul Meister family. Proceeds from the ...
By EvoEndo
-
`It was a life saver`: New London developed device for feeding tube insertions is a world first
Researchers in London, Ont., are the first in the world to use a new device for feeding tube insertion that can improve patient safety and reduce the cost of health-care services. A team from Lawson Health Research Institute has partnered with CoapTech LLC, a medical device company, to study the use of the PUMA-G System. In October of last year, the medical and research teams were the first in ...
By CoapTech
-
Nyxoah Announces CE-Mark Indication Approval to Treat Complete Concentric Collapse (CCC) Patients
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that DEKRA Notified Body has approved the Company’s proposed indication for the Genio® system to treat patients with a Complete ...
By Nyxoah SA
-
Amsel Medical wins FDA nod for Endo Occluder
Amsel Medical said today that it won FDA 510(k) clearance for its Amsel Endo Occluder device intended for occluding blood vessels during endoscopic procedures. The Cambridge, Mass.-based company touted that the clearance is the third the company has received from the FDA so far for its portfolio of occluder devices. The Amsel Endo Occluder is a mechanical occlusion clip delivered through a ...
-
Nyxoah Provides General Corporate Update
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today provided a general corporate update. 2021 Highlights Implanted first U.S. patient in the DREAM IDE pivotal study in December 2020; there are currently ...
By Nyxoah SA
-
ReShape Medical, Inc. Completes $38 Million Series D Financing
ReShape Medical® today announced that it has completed a Series D financing of $38 million led by HealthCor Partners Management, L.P. with participation from Endeavour Vision SA and existing investors, SV Life Sciences, New Leaf Venture Partners, U.S. Venture Partners and Venture Investors. The announcement follows the recent approval of the ReShape™ Integrated Dual Balloon System, a ...
-
EvoEndo and Micro-Tech Endoscopy Announce Partnership for Single-Use Unsedated Endoscopy System
EvoEndo®, Inc. (“EvoEndo”), a medical device company developing systems for unsedated endoscopy, today announced the signing of a distribution agreement with Micro-Tech Endoscopy USA, Inc. (“Micro-Tech”). The agreement, whereby Micro-Tech will distribute the EvoEndo® Single-Use Endoscopy System in the US, is expected to begin pending US FDA 510(k) clearance. ...
By EvoEndo
-
Mauna Kea Technologies Receives FDA 510(k) Clearance of Cellvizio® with a Fluorescent Dye, Fluorescein, as Drug Device Combination
The Cellvizio®100 series system with all its different Confocal Miniprobes™ is now cleared for use with the fluorescein dye to image blood flow in the microvasculature and capillaries Mauna Kea Technologies today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Cellvizio® 100 series and all associated Confocal Miniprobes™ for ...
-
ReShape Integrated Dual Balloon System to Fill Significant Gap in Obesity Treatment Spectrum
ReShape Medical today announced that the Company has submitted a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the ReShape Integrated Dual Balloon System, the first and only dual balloon for non-surgical weight loss designed for people with a 30-40 body mass index (BMI). The ReShape Integrated Dual Balloon System is the first device to meet its primary ...
-
Fractyl Announces Tenth Trial Site Opened in REVITA-T2Di Study of Revita DMR for Type 2 Diabetes
REVITA-T2Di study is assessing potential of outpatient Revita DMR treatment to improve glycemic control and reduce or eliminate need for daily insulin – LEXINGTON, Mass., September 1, 2021 – Fractyl Health, a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced the activation of the tenth ...
-
EndoLogic Acquires Renzapride from Alizyme, plc
EndoLogic, a company focused on the development and commercialization of products that treat gastrointestinal diseases, has acquired the worldwide rights to the clinical-stage asset, renzapride, from Alizyme, plc. Renzapride has been in clinical development for use as a prokinetic agent for the gastrointestinal tract. EndoLogic plans on developing the compound for the treatment of gastroparesis. ...
-
Early Trial Data Show Promise in Endoscopic Procedure Time Study
A STUDY EVALUATING ENDOSCOPIC PROCEDURE TIME REMOVING COMPLEX COLORECTAL POLYPS SHOWS SUPERIORITY OF LUMENDI’S DILUMEN DEVICE OVER A CONTROL GROUP. Connecticut-based medical device innovator Lumendi LLC reports that its 1:1 randomized trial of the DiLumen Endolumenal Interventional Platform (EIP) successfully met the primary endpoint of an IRB-approved 200-patient prospective study. The ...
By Lumendi Ltd.
-
Lumendi Reports Successful Enrollment Closure of Its Dilumen Endolumenal Interventional Platform (EIP) Study
A STUDY EVALUATING ENDOSCOPIC PROCEDURE TIME REMOVING COMPLEX COLORECTAL POLYPS SHOWS SUPERIORITY OF DILUMEN OVER CONTROL GROUP. Connecticut-based medical device innovator Lumendi, LLC reports that its 1:1 randomized trial of the DiLumen Endoluminal Interventional Platform (EIP) successfully met the primary endpoint of an IRB-approved 200-patient prospective study. The study ...
By Lumendi Ltd.
-
Fractyl Health Announces Publication of Pioneering New Model of Intestine’s Role in Metabolism
LEXINGTON, Mass., October 27, 2021 – Fractyl Health, a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, including type 2 diabetes (T2D), today announced the publication of an innovative new model of metabolism, the Metabolic Balance Model. The study synthesizes multiple streams of existing evidence from ...
-
Fractyl Announces First Patient Enrolled in Pivotal Study of Novel Procedural Therapy Revita® DMR for Type 2 Diabetes
Fractyl Laboratories Inc. (Fractyl), a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced the enrollment of the first patient in a pivotal clinical trial of Revita® DMR for patients with type 2 diabetes. The trial, called REVITA-T2Di, will evaluate the ability of a single Revita DMR treatment to ...
-
Atlantic Healthcare plc acquires global rights to renzapride for the treatment of gastrointestinal motility disorders
Atlantic Healthcare plc (“Atlantic Healthcare” or “Company”), a specialist pharmaceutical company focused on developing and commercializing therapeutics that address unmet patient needs and rare diseases, today announced that the Company has entered into an agreement to acquire the global rights to renzapride from EndoLogic LLC (“EndoLogic”). Renzapride is a ...
-
Omega Medical Imaging Announces Installation of AI Image-Guided Interventional Endoscopy Systems at Orlando Health
Sanford, Florida (February 21, 2022) — Omega Medical Imaging, the leading innovator in AI image-guided interventional systems for hospitals and healthcare facilities around the world, announced the installation of E-View.AI interventional endoscopy systems at Orlando Health. Located in downtown Orlando, the Orlando Health Digestive Health Institute is a national and international ...
-
SafeHeal closes €6.0 million financing round led by Sofinnova Partners
Mar 23, 2018 – This financing allows for the execution of the company’s clinical and regulatory market access program. SafeHeal, an early-stage medtech company specialized in digestive surgery and focused on the development of the Colovac device, announces today that it has closed a €6 million Series A financing round led by Sofinnova Partners. Based in ...
By SafeHeal
-
EvoEndo Announces US FDA 510(k) Clearance for Single-Use Unsedated Transnasal Endoscopy (TNE) System
EvoEndo’s Single-Use Endoscopy System or the “EvoEndo System” eliminates the need for general anesthesia or conscious sedation during routine upper endoscopic procedures The EvoEndo System is being distributed by Micro-Tech Endoscopy USA with commercial sales slated to begin following completion of first clinical cases at several pediatric facilities EvoEndo, Inc. ...
By EvoEndo
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you